- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04786457
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
27 ottobre 2021 aggiornato da: Kirsten Lyke, University of Maryland, Baltimore
A Phase 1, Open-Label Clinical Trial With Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC) Assessment of Healthy U.S. Adults Previously Primed With Tetravalent Dengue Virus Purified Inactivated Vaccine (TDEN-PIV) and Boosted With Tetravalent Dengue Virus Live Attenuated Vaccine Formulation (TDEN LAV)
The purpose of this research study is to test the protection of volunteers previously vaccinated with Tetravalent Dengue Virus (TDEN) Purified Inactivated Vaccine (PIV) with alum and boosted with TDEN live attenuated vaccine (LAV) formulation against a weakened form of an experimental dengue virus challenge.
The Investigators will also include people that have not received the study vaccine.
The Investigators are collecting information about how the vaccine protects against a dengue virus challenge as well as adding to knowledge about the safety of the challenge.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The purpose of this research study is to test the protection of volunteers previously vaccinated with Tetravalent Dengue Virus (TDEN) Purified Inactivated Vaccine (PIV) with alum and boosted with TDEN live attenuated vaccine (LAV) formulation against a weakened form of an experimental dengue virus challenge.
The Investigators will also include people that have not received the study vaccine.
The Investigators are collecting information about how the vaccine protects against a dengue virus challenge as well as adding to knowledge about the safety of the challenge.
The information will help Investigators develop vaccines to protect people from dengue.
Participation is voluntary.
The duration of participation will last for 180 days (six months).
After participants are exposed to the weakened dengue virus, the Investigators will follow them closely to measure their symptoms.
Like the flu, participants might expect to have a headache, rash, body aches, fever and chills or they may experience no symptoms whatsoever.
If a participant does develops symptoms, the Investigators will monitor him/her closely in a local hotel or a wing of our hospital to ensure safety and to treat symptoms if they occur.
Participants will be compensated for their time.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
17
Fase
- Fase 1
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21201
- University of Maryland, Baltimore, Center for Vaccine Development and Global Health
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 18 anni a 50 anni (Adulto)
Accetta volontari sani
Sì
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- 1. Male or non-pregnant, non-breastfeeding female between 18 and 50 years of age (inclusive) at the time of consent.
- 2. Tetravalent dengue antibody response at 28 days following final vaccination for vaccinated groups of volunteers.
- 3. Volunteers must be able and willing to provide written informed consent.
- 4. Volunteers must be healthy as established by medical history and clinical examination at study entry.
- 5. Volunteers must pass a comprehension test and be able to comply with all study requirements.
- 6. Female volunteers of non-childbearing potential (non-childbearing potential is defined as having had one of the following: a tubal ligation at least 3 months prior to enrollment, a hysterectomy, an oophorectomy, or is post-menopausal).
- 7. Female volunteers of childbearing potential may be enrolled in the study, if all of the following apply:
- Practiced adequate contraception (see Definition of Terms, section 5.4.2.3.) for 30 days prior to challenge
- Has a negative urine pregnancy test on the day of DHIM
- Agrees to continue adequate contraception until two months after completion of the DHIM
- 8. Provide consent for release of medical history records from primary care physician, college or university medical center, urgent care, or emergency room visit
Exclusion Criteria:
- 1. Planned travel during the study period (180 days) which would interfere with the ability to complete all study visits
- 2. Recent (in the past 4 weeks) travel to any dengue endemic area. These potential volunteers may be eligible for enrollment a minimum of 4 weeks later
- 3. Volunteer seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV)
- 4. Unvaccinated volunteers positive for antibodies to flaviviruses (FV) to include dengue virus, West Nile virus, Yellow Fever virus, Zika virus, and Japanese encephalitis virus.
- 5. Any history of FV infection or FV vaccination except for participation in the ADVP003 or ADVP004 dengue vaccination studies; during the study period (Note: Late time point serology from the trials can be tested concomitant to screening serology to clarify if incident FV infection has occurred between vaccination and challenge)
- 6. Medical history of, or current, diabetes, chronic obstructive pulmonary disease, peptic ulcer disease, coronary artery disease, cardiac arrhythmia, cardiomyopathy, pericarditis, or auto-immune disease
- 7. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- 8. History of Guillain-Barré syndrome (GBS)
- 9. History of bipolar disorder, schizophrenia, hospitalization in the past year for a mental health disorder, or any other psychiatric condition, which in the opinion of the investigator prevents the volunteer from participating in the study
- 10. Safety laboratory test results at screening that are deemed clinically significant or more than Grade 1 deviation from normal with the exception of PT/PTT, fibrinogen decrease, ALT/AST increase (<1.1 x ULN acceptable), platelet decrease which will be exclusionary at Grade 1 or higher
- 11. Significant screening physical examination abnormalities at the discretion of the investigator, including a BMI > 35 kg/m2
- 12. Women who intend to become pregnant or men who intend to father a child during the study period (approximately 6 months)
- 13. Female: pregnant, lactating or history of heavy menstrual bleeding menstrual periods lasting consistently and regularly longer than 6 days, or consistently and regularly requiring 5 or more pads or tampons per day, and volunteer to the opinion and review of the investigator.
- 14. Female volunteers using an intrauterine device (IUD) or Mirena®
- 15. Female volunteers with a history of clinically significant fibroids or uterine polyps, endometriosis, dysmenorrhea, adenomyosis, and uterine scarring (e.g. after D&C), unless treated, with no active clinically significant disease
- 16. Allergy (hives, shortness of breath, swelling of the lips or throat), or hospitalization related to a previous vaccination, anaphylaxis of unknown etiology, or allergy to specific medications/animals for which antigens may be in the virus preparations to include: Shellfish allergy, Fetal Bovine Serum, L-Glutamine, Neomycin and Streptomycin
- 17. Recent blood donation within prior 56 days of inoculation or planning to donate blood in the one 1 year following inoculation with dengue virus
- 18. Receipt of blood products or antibodies within 90 days of inoculation or during the study period
- 19. Any personal beliefs that bar the administration of blood products, transfusions, or serum albumin
- 20. Participation in the 4 weeks preceding inoculation, or planned participation during the present trial period, in another clinical trial investigating a vaccine except for participation in the ADVP003 or ADVP004 study, drug, medical device, or medical procedure
- 21. Planned administration of a licensed or study vaccine not planned in the study protocol during the period starting 30 days prior to the DHIM for a live vaccine or 14 days prior to DHIM for inactivated vaccines and extending until 56 days after study completion
- 22. Planned or current administration of an HMG-CoA reductase inhibitor (i.e., lovastatin, simvastatin, atorvastatin, etc.)
- 23. Currently taking methadone or suboxone
- 24. Currently regularly taking anti-coagulant medication, aspirin or non-steroidal anti-inflammatory drugs (NSAIDs)
- 25. Chronic migraine headaches, defined as more than 15 headache days per month over a 3-month period of which more than 8 are migraines, in the absence of medication over use
- 26. Chronic or recent acute medical condition that, in the opinion of the investigator, impacts volunteer safety.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
open-label injection of DENV-1-LVHC to 15-20 adults who were previously vaccinated and 5 adults who have never received a dengue vaccination
|
one subcutaneous injection of Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) at 0.5 mL of 6.5 x 10^3 PFU/mL
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Incidenza di misurazioni di laboratorio anormali
Lasso di tempo: circa sei mesi
|
Incidenza di misurazioni di laboratorio anormali fino a 28 giorni dopo l'inoculazione del virus o 7 giorni dopo il ricovero in ospedale, a seconda di quale sia il successivo
|
circa sei mesi
|
Solicited Injection Site Adverse Events
Lasso di tempo: approximately six months
|
solicited injection site adverse event until 7 days post virus inoculation
|
approximately six months
|
Unsolicited Injection Site Adverse Events
Lasso di tempo: approximately six months
|
unsolicited injection site adverse events until 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
approximately six months
|
Solicited Systemic Adverse Events
Lasso di tempo: approximately six months
|
solicited systemic adverse events until 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
approximately six months
|
Dengue-Related Adverse Events
Lasso di tempo: approximately six months
|
dengue-related like adverse events until 28 days post virus inoculation or 7 days post inpatient whichever is later
|
approximately six months
|
Unsolicited Systemic Adverse Events
Lasso di tempo: approximately six months
|
unsolicited systemic adverse events until 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
approximately six months
|
Short-Term SAEs
Lasso di tempo: approximately six months
|
Number of SAEs until 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
approximately six months
|
Long-Term SAEs
Lasso di tempo: approximately seven months
|
Number of SAEs until 6 months post virus inoculation
|
approximately seven months
|
Fever
Lasso di tempo: approximately seven months
|
The occurrence of fever defined as greater than or equal to 38°C (100.4°
F) measured at least 2 times at least 4 hours apart
|
approximately seven months
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
30 novembre 2020
Completamento primario (Effettivo)
9 luglio 2021
Completamento dello studio (Effettivo)
9 luglio 2021
Date di iscrizione allo studio
Primo inviato
24 novembre 2020
Primo inviato che soddisfa i criteri di controllo qualità
3 marzo 2021
Primo Inserito (Effettivo)
8 marzo 2021
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
28 ottobre 2021
Ultimo aggiornamento inviato che soddisfa i criteri QC
27 ottobre 2021
Ultimo verificato
1 ottobre 2021
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- HP-00088798
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Sì
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
-
State University of New York - Upstate Medical...Walter Reed Army Institute of Research (WRAIR); U.S. Army Medical Research and...Attivo, non reclutante
-
U.S. Army Medical Research and Development CommandState University of New York - Upstate Medical UniversityCompletato
-
State University of New York - Upstate Medical...U.S. Army Medical Research and Development Command; Janssen Pharmaceutica N.V...Completato
-
University of Maryland, BaltimoreMedical Technology Enterprise Consortium (MTEC)Completato
-
State University of New York - Upstate Medical...Walter Reed Army Institute of Research (WRAIR); U.S. Army Medical Research and...Completato
-
Serum Institute of India Pvt. Ltd.PPD Australia Pty LtdCompletatoPrevenzione della febbre dengueAustralia